PROTEOMICS The Proteomics Core is a new core for the Cancer Center but has been supporting Cancer Center investigators for two years. The primary goal of the Proteomics Core is to provide affordable access to a broad range of high-throughput, cutting-edge proteomics services. General proteomics services provided by the core include proteome mapping, protein expression profiling, mapping of post-translational modifications, and analysis of protein complexes. Specific technologies used by the Core include tandem mass spectrometry, capillary HPLC, 2D gel electrophoresis, 2D LCMSMS, ITRAQ analysis, and related technologies. The Proteomics Core is directed by Dr. Philip Andrews and the Associate Director, Dr. John Strahler. General management is by the senior management committee, consisting of the Director, Associate Director, Manager of the 2D gel lab (Mary Hurley), Manager of the LIMS development and maintenance group (David Lentz), and the Business Manager for the Core (Katherine Wood). The infrastructure for the core includes 5 mass spectrometers, 2 sample processing robots, imaging systems, electrophoresis apparatuses, 4 capillary HPLCs, and other equipment used for proteome analysis. The Core has an extensive IT infrastructure, including a LIMS system, mass storage devices, a linux cluster, several servers supporting database search engines for proteomics, and an online business system. The 13 personnel in the core includes 4 PhDs and represents an aggregate of more than 70 years experience in proteomics and mass spectrometry.
| Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224 |
| Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224 |
| Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757 |
| Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605 |
| Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820 |
| Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458 |
| Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666 |
| Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3: |
| Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647 |
| Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4 |
Showing the most recent 10 out of 1493 publications
